Upregulation of stem cell genes in multidrug resistant K562 leukemia cells

被引：28
作者：
Lehne, Gustav [1 ,2 ]
Grasmo-Wendler, Unn-Hilde
Berner, Jeanne-Marie
Meza-Zepeda, Leonardo A. [4 ]
Adamsen, Birgitte Lid [3 ]
Flack, Aksel [4 ]
Reiner, Andrew [4 ]
Clausen, Ole Petter Fraas [3 ]
Hovig, Eivind
Myklebost, Ola [4 ]
机构：
[1] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway
[2] Oslo Univ Hosp, Rikshosp, Dept Clin Pharmacol, N-0310 Oslo, Norway
[3] Oslo Univ Hosp, Rikshosp, Dept Pathol, N-0310 Oslo, Norway
[4] Univ Oslo, Dept Mol Biosci, Norwegian Microarray Consortium, N-0316 Oslo, Norway
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷 / 10期
关键词：
Stem cells; Gene amplification; Multidrug resistance; ABCB1; ABCB4; ABCB5; SEMA3D; P-GLYCOPROTEIN; DRUG-RESISTANCE; CD38; EXPRESSION; IN-VITRO; INHIBITION; APOPTOSIS; LINES; BRAIN; MDR1; GLUCOSYLCERAMIDE;
D O I：
10.1016/j.leukres.2009.03.028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The transmembrane transporter P-glycoprotein (P-gp) encoded by ABCB1, is one major cause for multidrug resistance (MDR). We compared the genomic profile and gene expression pattern of the P-gp positive K562(VCR) cells with parental P-gp negative K562(wt) cells. In K562VCR array CGH revealed amplification of ABCB1, ABCB4, ABCB5 and SEMA3D, whereas expression microarrays demonstrated upregulation of stem cell genes (e.g. KIT and HOXB4), anti-apoptotic genes (e.g. IGF1R and CCNG1), and downregulation of proapoptotic genes (e.g. CASP4, 6 and 7). Thus, K562VCR cells disclose stem cell characteristics including a range of drug resistance mechanisms possibly attained as a stem cell program switched on en bloc. (c) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1379 / 1385
页数：7
相关论文
共 49 条
[1]   Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction [J].
Anglicheau, D. ;
Pallet, N. ;
Rabant, M. ;
Marquet, P. ;
Cassinat, B. ;
Meria, P. ;
Beaune, P. ;
Legendre, C. ;
Thervet, E. .
KIDNEY INTERNATIONAL, 2006, 70 (06) :1019-1025
[2]   Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance [J].
Annereau, JP ;
Szakacs, G ;
Tucker, CJ ;
Arciello, A ;
Cardarelli, C ;
Collins, J ;
Grissom, S ;
Zeeberg, BR ;
Reinhold, W ;
Weinstein, JN ;
Pommier, Y ;
Paules, RS ;
Gottesman, MM .
MOLECULAR PHARMACOLOGY, 2004, 66 (06) :1397-1405
[3]   Association of ABCA1 with syntaxin 13 and flotillin-1 and enhanced phagocytosis in Tangier cells [J].
Bared, SM ;
Buechler, C ;
Boettcher, A ;
Dayoub, R ;
Sigruener, A ;
Grandl, M ;
Rudolph, C ;
Dada, A ;
Schmitz, G .
MOLECULAR BIOLOGY OF THE CELL, 2004, 15 (12) :5399-5407
[4]   Targeting endothelial and tumor cells with semaphorins [J].
Bielenberg, Diane R. ;
Klagsbrun, Michael .
CANCER AND METASTASIS REVIEWS, 2007, 26 (3-4) :421-431
[5]   Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo [J].
Bunting, KD ;
Zhou, S ;
Lu, TH ;
Sorrentino, BP .
BLOOD, 2000, 96 (03) :902-909
[6]   Characterization of drug-resistant cell lines by comparative genomic hybridization [J].
Carlson, KM ;
Gruber, A ;
Liliemark, E ;
Larsson, R ;
Nordenskjöld, M .
CANCER GENETICS AND CYTOGENETICS, 1999, 111 (01) :32-36
[7]   Conversion of CD38 and/or myeloid-associated marker expression status during the course of B-CLL: association with a change to an aggressive clinical course [J].
Chang, CC ;
Cleveland, RP .
BLOOD, 2002, 100 (03) :1106-1106
[8]   CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia [J].
D'Arena, G ;
Musto, P ;
Cascavilla, N ;
Dell'Olio, M ;
Di Renzo, N ;
Perla, G ;
Savino, L ;
Carotenuto, M .
LEUKEMIA & LYMPHOMA, 2001, 42 (1-2) :109-114
[9]   Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and γ-irradiation [J].
Damiano, JS ;
Hazlehurst, LA ;
Dalton, WS .
LEUKEMIA, 2001, 15 (08) :1232-1239
[10]   Tumour stem cells and drug resistance [J].
Dean, M ;
Fojo, T ;
Bates, S .
NATURE REVIEWS CANCER, 2005, 5 (04) :275-284
12345